Generic drug

Sun Pharmaceuticals Industries Ltd Q3FY24; 17% rise in Profits

● Jan 31, 2024

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and...

Pfizer Ltd Q2FY24; 52% fall in Profits

● Nov 20, 2023

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility...

Sanofi India Ltd Q2FY24; 16% rise in Profits

● Nov 9, 2023

Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products. Financial Results: Sanofi India Ltd reported Revenues...

Strides Pharma Science Ltd Q2FY24; 11% rise in Revenue

● Oct 30, 2023

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company’s pharmaceutical products are...

Torrent Pharmaceuticals Ltd Q1FY24; 7% rise in Profits

● Aug 7, 2023

Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic...

Torrent Pharmaceuticals Ltd Q4FY23 revenue grows by 17%

● May 30, 2023

Torrent Pharmaceuticals Ltd reported Total revenue for Q4 FY23 of ₹2,452 Crore, up from ₹ Crore year on year depicting...

Dr. Reddy’s Laboratories: One Of The Major Player In Generic Segment

● Apr 11, 2023

“We are progressing well on our pipeline products. The number of filings in several of our key markets have been...

Torrent pharma Q3FY23 net profit rises by 14 percent

● Feb 24, 2023

Torrent Pharma reported that its consolidated net profit increased by 14 per cent to INR 283 crore in the third...

Wockhardt posted a net loss of INR 102 Crores in Q3FY23

● Feb 21, 2023

Drugmaker Wockhardt posted a consolidated loss of ₹102 crore for the three months ended December 31, 2022. The company posted...

Zydus lifescience net profit soars by 23% in Q3FY23

● Feb 10, 2023

Zydus Lifesciences Ltd reported a 23 per cent rise in consolidated net profit at INR 631 crore for the third...